{"id":27731,"date":"2015-11-30T16:34:27","date_gmt":"2015-11-30T11:04:27","guid":{"rendered":"http:\/\/www.scconline.com\/blog\/?p=27731"},"modified":"2015-12-22T12:17:11","modified_gmt":"2015-12-22T06:47:11","slug":"erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/","title":{"rendered":"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company"},"content":{"rendered":"

Delhi High Court: <\/strong>While addressing to the issue of patent violation, the Court concluded that Cipla (Defendant) was infringing on Swiss pharmaceutical company Hoffman-La Roche’s (Plaintiff) patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva. Cipla\u2019s drug named Erlocip, used for treatment of non-small cell lung cancer, violated the patent rights of Hoffman la Roche, which had patented the basic medicinal compound. The division bench comprising of Pradeep Nandrajog and Mukta Gupta JJ., ruled in favour of Roche after noting that Cipla’s lung cancer medicine, Erlocip, was one polymorphic form of the erlotinib hydrochloride compound, which may exist in several forms, and Roche’s patent claim was not limited to any one such version.<\/p>\n

The bench said, “This (the patent) is a sufficiently broad claim that is clearly not limited to any polymorphic version of erlotinib hydrochloride, but to erlotinib hydrochloride itself. This compound may exist in several polymorphic forms, but any and all such forms will be subsumed within this patent. Therefore, as Cipla’s Erlocip is admittedly one particular polymorphic form of the erlotinib hydrochloride compound (polymorph B), it will clearly infringe the IN 774 patent (of Roche)…We thus conclude this issue by noting that the single judge’s finding that ‘Tarceva’ and ‘Erlocip’ were based on the polymorph B version of erlotinib hydrochloride, though correct factually, is irrelevant to the subject matter of the present patent as Cipla has clearly infringed Claim 1 of Roche’s IN 774 patent in arriving at the said polymorph.\u201d<\/p>\n

The bench held that the Cipla drug violated the Roche patent, but has at the same time refused to issue any injunction against Cipla restraining it from manufacturing the medicine, after observing that the life of the patent granted to Roche was ending in March 2016. The Court held\u201c\u2026keeping in view the fact that the life of the patent in favour of Roche in India would expire in March, 2016 we do not grant the injunction as prayed for by Roche against Cipla (because as noted above there was no interim injunction in favour of Roche and due to said reason Cipla continued to manufacture and sell Erlocip),\u201d. It has also imposed case costs of Rs 5 lakh on Cipla to be given to Roche. [Hoffman la Roche Ltd. v. Cipla Ltd.<\/em>, 2015 SCC OnLine Del 13619<\/a><\/b>, decided on 27-11-2015]<\/p>\n","protected":false},"excerpt":{"rendered":"

Delhi High Court: While addressing to the issue of patent violation, the Court concluded that Cipla (Defendant) was infringing on Swiss pharmaceutical <\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3,10],"tags":[4051],"class_list":["post-27731","post","type-post","status-publish","format-standard","hentry","category-casebriefs","category-highcourts","tag-cipla"],"yoast_head":"\n\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company | SCC Times<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company\" \/>\n<meta property=\"og:description\" content=\"Delhi High Court: While addressing to the issue of patent violation, the Court concluded that Cipla (Defendant) was infringing on Swiss pharmaceutical\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-30T11:04:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-12-22T06:47:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1329\" \/>\n\t<meta property=\"og:image:height\" content=\"888\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sucheta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sucheta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/\",\"name\":\"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company | SCC Times\",\"isPartOf\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\"},\"datePublished\":\"2015-11-30T11:04:27+00:00\",\"dateModified\":\"2015-12-22T06:47:11+00:00\",\"author\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.scconline.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\",\"url\":\"https:\/\/www.scconline.com\/blog\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.scconline.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa\",\"name\":\"Sucheta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g\",\"caption\":\"Sucheta\"},\"url\":\"https:\/\/www.scconline.com\/blog\/post\/author\/legal_editor\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company | SCC Times","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/","og_locale":"en_US","og_type":"article","og_title":"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company","og_description":"Delhi High Court: While addressing to the issue of patent violation, the Court concluded that Cipla (Defendant) was infringing on Swiss pharmaceutical","og_url":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2015-11-30T11:04:27+00:00","article_modified_time":"2015-12-22T06:47:11+00:00","og_image":[{"width":1329,"height":888,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/10\/Delhi-HC.jpg","type":"image\/jpeg"}],"author":"Sucheta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sucheta","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/","url":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/","name":"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"datePublished":"2015-11-30T11:04:27+00:00","dateModified":"2015-12-22T06:47:11+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa"},"breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/7416b8c43cd3a0a3412cf97fc17b54fa","name":"Sucheta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/530d4c250404c869212316d6351878b83f86bf27648031b1e6d4857a4bae4b88?s=96&d=mm&r=g","caption":"Sucheta"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/legal_editor\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":296408,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/07\/10\/delhi-hc-denies-interim-injunction-to-bayer-healthcare-for-drug-regorafenib-legal-news\/","url_meta":{"origin":27731,"position":0},"title":"\u2018Public interest demands easy, affordable access to anti-cancer drug\u2019; Delhi High Court denies interim injunction to Bayer Healthcare for drug \u2018Regorafenib\u2019","author":"Simranjeet","date":"July 10, 2023","format":false,"excerpt":"Bayer healthcare LLC was selling its product of Rs. 36,995 by importing the same into India, whereas the Natco Pharma Ltd. was manufacturing the product in India and selling the same of Rs. 9,900. The injunction was refused due to the huge disparity between the prices offered by both, for\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"delhi high court","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/05\/delhi-high-court.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":250896,"url":"https:\/\/www.scconline.com\/blog\/post\/2021\/07\/08\/spreading-strains-of-sars-cov-2\/","url_meta":{"origin":27731,"position":1},"title":"Spreading strains of SARS-CoV-2: The need to rethink utility patents","author":"Editor","date":"July 8, 2021","format":false,"excerpt":"by Shruti Prasad Dhonde","rel":"","context":"In "Op Eds"","block_context":{"text":"Op Eds","link":"https:\/\/www.scconline.com\/blog\/post\/category\/op-ed\/legal-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-4-3.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-4-3.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-4-3.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-4-3.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/07\/MicrosoftTeams-image-4-3.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":42501,"url":"https:\/\/www.scconline.com\/blog\/post\/2016\/04\/07\/cipla-vet-pty-ltd-ordered-to-deliver-all-infringing-fiprotec-products-in-its-possession-or-under-its-control\/","url_meta":{"origin":27731,"position":2},"title":"Cipla Vet (Pty) Ltd ordered to deliver all infringing Fiprotec products in its possession or under its control","author":"Sucheta","date":"April 7, 2016","format":false,"excerpt":"Supreme Court of Appeal of South Africa:\u00a0Deciding on an appeal which concerns infringement of a patent entitled \u2018Anti-parasitic composition for the treatment and protection of pets\u2019 by the respondent and challenge of invalidity of the patent by the respondent on the basis of lack of clarity, the Court by a\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/03\/Supreme-Court-of-Appeals.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/03\/Supreme-Court-of-Appeals.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/03\/Supreme-Court-of-Appeals.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/03\/Supreme-Court-of-Appeals.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/03\/Supreme-Court-of-Appeals.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":356012,"url":"https:\/\/www.scconline.com\/blog\/post\/2025\/08\/08\/del-hc-can-invoke-sec-104a-patents-act-for-disclosure-manufacturing-process\/","url_meta":{"origin":27731,"position":3},"title":"S. 104A of Patents Act can be invoked at interim stage for disclosure of manufacturing process : Inside Delhi HC verdict in Roche\u2019s plea seeking disclosure of Zydus\u2019s \u2018Sigrima\u2019 process","author":"Editor","date":"August 8, 2025","format":false,"excerpt":"The intent behind Section 104A of the Act is to shift the onus of proof from the plaintiff to the defendant in cases involving infringement of process patents. This is premised on the fact that the process adopted by a defendant in manufacturing its product would only be known to\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"Delhi HC Section 104A Patents Act","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/08\/delhi-80197898.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/08\/delhi-80197898.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/08\/delhi-80197898.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/08\/delhi-80197898.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":18422,"url":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/","url_meta":{"origin":27731,"position":4},"title":"Glenmark restrained from manufacturing and selling its anti-diabetes drugs","author":"Sucheta","date":"October 8, 2015","format":false,"excerpt":"Delhi High Court: In granting permanent injunction to US drug company Merck Sharp and Dohme (MSD), the Court restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs \"Zita\" and \"Zita-Met\", saying it has infringed patent of the plaintiff. The US drug maker in its plea had sought\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":217059,"url":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/19\/del-hc-interim-stay-on-natco-pharmas-generic-drug-apigat-quashed-importance-of-the-3-elements-while-granting-interim-injunction-in-pharmaceutical-patent-cases-stressed-up\/","url_meta":{"origin":27731,"position":5},"title":"Del HC | Interim stay on Natco Pharma\u2019s generic drug APIGAT quashed; importance of the \u20183 elements\u2019 while granting interim injunction in pharmaceutical patent cases stressed upon\u00a0","author":"Bhumika Indulia","date":"July 19, 2019","format":false,"excerpt":"Delhi High Court: The Division Bench of Dr S. Muralidhar and Talwant Singh, JJ. allowed the appeal filed by Natco Pharma Ltd. and quashed the order of the Single Judge restraining Natco Pharma from infringing the suit patent held by Bristol Myers.\u00a0 The plaintiff, Bristol Myers is a company incorporated\u2026","rel":"","context":"In "Case Briefs"","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/27731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=27731"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/27731\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=27731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=27731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=27731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}